Active substance
Insulin aspart recombinant
- US FDA 5
- US price lines 3
- Safety 7
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| NOVOLOG | 1000 UNITS/10ML (100 UNITS/ML) | injectable · subcutaneous | NOVO NORDISK INC | Prescription | 7 Jun 2000 |
| NOVOLOG PENFILL | 300 UNITS/3ML (100 UNITS/ML) | injectable · subcutaneous | NOVO NORDISK INC | Prescription | 7 Jun 2000 |
| NOVOLOG FLEXPEN | 300 UNITS/3ML (100 UNITS/ML) | injectable · subcutaneous | NOVO NORDISK INC | Prescription | 7 Jun 2000 |
| NOVOLOG INNOLET | 300 UNITS/3ML (100 UNITS/ML) | injectable · subcutaneous | NOVO NORDISK INC | Discontinued | 7 Jun 2000 |
| NOVOLOG FLEXTOUCH | 300 UNITS/3ML (100 UNITS/ML) | injectable · subcutaneous | NOVO NORDISK INC | Discontinued | 7 Jun 2000 |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | NOVOLOG 100 UNIT/ML FLEXPEN | $8.93506 | per ML | 23 Sep 2026 |
| US NADAC | NOVOLOG 100 UNIT/ML VIAL | $6.93519 | per ML | 23 Sep 2026 |
| US NADAC | NOVOLOG PENFILL 100 UNIT/ML | $8.56929 | per ML | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 28 Feb 2023 NOVOLOG — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 28 Feb 2023 NOVOLOG FLEXPEN — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 28 Feb 2023 NOVOLOG FLEXTOUCH — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 28 Feb 2023 NOVOLOG INNOLET — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 28 Feb 2023 NOVOLOG PENFILL — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 28 Apr 2021 NOVOLOG MIX 70/30 — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 15 Nov 2019 NOVOLOG MIX 50/50 — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.